Press Releases Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
44.24 ^USD	+0.89%		+4.41%	-7.49%

Apr. 22	RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	MT
Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	Apr. 25	GL
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - April 19, 2024	Apr. 22	AQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 19	GL
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	Apr. 15	AQ
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15	GL
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	Apr. 12	GL
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	Apr. 12	GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Mar. 25	AQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 22	GL
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 22	AQ
Ultragenyx to Participate at Investor Conferences in March	Feb. 27	GL
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Feb. 26	AQ
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Feb. 23	GL
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Feb. 23	AQ
Ultragenyx: Q4 Earnings Snapshot	Feb. 15	AQ
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	Feb. 15	GL
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	Feb. 15	AQ
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update	Feb. 08	GL
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function	Feb. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Press Releases

Filters